FRA:JNJ - Deutsche Boerse Ag - US4781601046 - Common Stock - Currency: EUR
FRA:JNJ (5/21/2025, 12:23:39 PM)
135.3
-1.08 (-0.79%)
The current stock price of JNJ.DE is 135.3 EUR. In the past month the price decreased by -1.72%. In the past year, price decreased by -0.25%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 54.47 | 632.02B | ||
LLY.DE | ELI LILLY & CO | 53.72 | 623.30B | ||
ZEG.DE | ASTRAZENECA PLC | 18.9 | 384.91B | ||
1JNJ.MI | JOHNSON & JOHNSON | 15.12 | 325.25B | ||
NOV.DE | NOVO NORDISK A/S-B | 19.55 | 267.28B | ||
RHO.DE | ROCHE HOLDING AG-BR | 14.85 | 241.16B | ||
SNW.DE | SANOFI | 13.9 | 229.07B | ||
SAN.PA | SANOFI | 13.87 | 228.50B | ||
1SAN.MI | SANOFI | 13.71 | 225.86B | ||
NOT.DE | NOVARTIS AG-REG | 13.53 | 196.98B | ||
1MRKX.MI | MERCK & CO. INC. | 10 | 174.39B | ||
6MK.DE | MERCK & CO. INC. | 9.9 | 172.62B |
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,100 full-time employees. The firm's primary focus is products related to human health and well-being. The firm operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.
JOHNSON & JOHNSON
One Johnson & Johnson Plaza
New Brunswick NEW JERSEY US
Employees: 138100
Phone: 17325242455
The current stock price of JNJ.DE is 135.3 EUR. The price decreased by -0.79% in the last trading session.
The exchange symbol of JOHNSON & JOHNSON is JNJ and it is listed on the Deutsche Boerse Ag exchange.
JNJ.DE stock is listed on the Deutsche Boerse Ag exchange.
30 analysts have analysed JNJ.DE and the average price target is 153.83 EUR. This implies a price increase of 13.69% is expected in the next year compared to the current price of 135.3. Check the JOHNSON & JOHNSON stock analysts ratings, price target forecast and up-and down grades for more detailed information.
JOHNSON & JOHNSON (JNJ.DE) has a market capitalization of 325.54B EUR. This makes JNJ.DE a Mega Cap stock.
JOHNSON & JOHNSON (JNJ.DE) currently has 138100 employees.
JOHNSON & JOHNSON (JNJ.DE) has a support level at 136.36 and a resistance level at 136.44. Check the full technical report for a detailed analysis of JNJ.DE support and resistance levels.
The Revenue of JOHNSON & JOHNSON (JNJ.DE) is expected to grow by 2.89% in the next year. Check the estimates tab for more information on the JNJ.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
JOHNSON & JOHNSON (JNJ.DE) has a dividend yield of 3.48%. The yearly dividend amount is currently 4.39. Check the full fundamental report for a detailed analysis of JNJ.DE dividend history, reliability and sustainability.
JOHNSON & JOHNSON (JNJ.DE) will report earnings on 2025-07-16, before the market open.
The PE ratio for JOHNSON & JOHNSON (JNJ.DE) is 15.13. This is based on the reported non-GAAP earnings per share of 8.94 and the current share price of 135.3 EUR. Check the full fundamental report for a full analysis of the valuation metrics for JNJ.DE.
ChartMill assigns a fundamental rating of 5 / 10 to JNJ.DE. Both the profitability and the financial health of JNJ.DE get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months JNJ.DE reported a non-GAAP Earnings per Share(EPS) of 8.94. The EPS decreased by -3.92% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 24.41% | ||
ROA | 11.26% | ||
ROE | 27.92% | ||
Debt/Equity | 0.63 |
ChartMill assigns a Buy % Consensus number of 74% to JNJ.DE. The Buy consensus is the average rating of analysts ratings from 30 analysts.
For the next year, analysts expect an EPS growth of 7.29% and a revenue growth 2.89% for JNJ.DE